Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis - Related Studies

Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

This study is currently recruiting participants.

Study NCT00029107. Last updated on October 10, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Hepatitis C
		Vasculitis

2	Additional conditions recognized in this trial
		Hepatitis

3	More general conditions related to this trial
		Cardiovascular Diseases
		Digestive System Diseases
		Flaviviridae Infections
		Hepatitis, Viral, Human
		Liver Diseases
		RNA Virus Infections
		Vascular Diseases
		Virus Diseases

4	Interventions listed in this trial
		Rituximab

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Antirheumatic Agents
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)